HIGHLIGHTS
- who: ufeffAbbasufeff ufeffYadegarufeff from the University of Cambridge, United Kingdom have published the article: Rapid-format recombinant antibody-based methods for the diagnosis of ufeffClostridioides difficileufeff infection: Recent advances and perspectives, in the Journal: (JOURNAL)
SUMMARY
20-30% of the patients with primary infection symptoms experience recurrent disease within 2-6 weeks after the completion of antibiotic treatment (Cornely et_al, 2012; Raeisi et_al, 2022a), which would be higher after secondary and tertiary CDI and more refractory to treatment regimens (Cornely et_al, 2012; Eze et_al, 2017). In recent years, antibodies, i.e., polyclonal (pAb . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.